RT Journal Article
SR Electronic
T1 Trans-Ancestry GWAS of Hot Flashes Reveals Potent Treatment Target and Overlap with Psychiatric Disorders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.12.24313572
DO 10.1101/2024.09.12.24313572
A1 Werwath, Kathryn E.
A1 Lawn, Rebecca B.
A1 Salem, Madeleine T.
A1 Li, Tayden
A1 Mitchell, Brittany L.
A1 Shen, Hanyang
A1 Gordon, Scott D.
A1 Kung, Benson
A1 Stafford, Ciera
A1 Vemuri, Mytilee
A1 Ratanatharathorn, Andrew
A1 Meijsen, Joeri
A1 Shadyab, Aladdin H.
A1 Kooperberg, Charles
A1 Koenen, Karestan C.
A1 Crandall, Carolyn J.
A1 Martin, Nicholas G.
A1 Duncan, Laramie E.
YR 2024
UL http://medrxiv.org/content/early/2024/09/13/2024.09.12.24313572.abstract
AB Background Most women experience hot flashes (hot flushes) during the menopause transition. Menopausal hot flashes typically persist for years. For a sizeable minority of women, hot flashes are severe and substantially impairing. It is worthwhile to further investigate the genetic underpinnings of hot flashes.Method We conducted the largest trans-ancestry genome-wide association study (GWAS) of hot flashes available to date (N=149,560). We used self-assessment of hot flashes in the Nurses’ Health Study, Nurses’ Health Study II, Women’s Health Initiative, and Queensland Institute of Medical Research samples (total n=42,489). In one sample (UK Biobank, n=107,071) direct assessment of hot flashes was not available, so menopausal hormone therapy was used as a proxy variable. We estimated the heritability of hot flashes and genetic correlations with psychiatric phenotypes using linkage disequilibrium score regression (LDSR).Results In component analyses and our trans-ancestry meta-analysis, the top locus was on chromosome 4 in the neurokinin 3 receptor gene (TACR3, position 104,556,732, trans-ancestry p=7.2×10−41). A second novel locus was identified (LINC02428, p=3.5×10−8). Gene results implicated TACR3, GRID1, NUDT4, and PHF21B. Using the hot flash GWAS meta-analysis (n=42,489; i.e., no proxy variable), SNP heritability was estimated: h2liab=.08 (h2SNP=.04, se=.02). Genetic correlations were statistically significant between hot flashes and posttraumatic stress disorder (PTSD, rg=0.25, p=0.01), schizophrenia (rg=0.17, p=0.02), and depression (rg=0.21, p=0.01).Discussion These genomic findings are consistent with independent, robust basic science research which led to a novel treatment for hot flashes, namely, neurokinin 3 receptor antagonists. This new class of hot flash drugs blocks the receptor (neurokinin 3 receptor) coded for by the top locus for hot flashes (TACR3). This GWAS of hot flashes provides an uncommonly clear example of how GWAS findings can point to potent treatment targets for complex brain phenotypes. We also found that the proxy variable (menopausal hormone therapy) pointed to the same target (TACR3), and that exclusively intronic and intergenic variants signaled this target.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Mental Health (NIMH) R01 MH123486 & R21 MH125358 to LD and by the Jaswa Innovator award to LD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Stanford University determined that this work does not meet criteria for human subjects research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData availability is dependent upon regulations specific to each of the datasets analyzed here. None are publicly available without approval. Rather, relevant access procedures must be followed to obtain access to datasets including the UK Biobank.